Literature DB >> 24145037

Biased agonism as a mechanism for differential signaling by chemokine receptors.

Sudarshan Rajagopal1, Daniel L Bassoni, James J Campbell, Norma P Gerard, Craig Gerard, Tom S Wehrman.   

Abstract

Chemokines display considerable promiscuity with multiple ligands and receptors shared in common, a phenomenon that is thought to underlie their biochemical "redundancy." Their receptors are part of a larger seven-transmembrane receptor superfamily, commonly referred to as G protein-coupled receptors, which have been demonstrated to be able to signal with different efficacies to their multiple downstream signaling pathways, a phenomenon referred to as biased agonism. Biased agonism has been primarily reported as a phenomenon of synthetic ligands, and the biologic prevalence and importance of such signaling are unclear. Here, to assess the presence of biased agonism that may underlie differential signaling by chemokines targeting the same receptor, we performed a detailed pharmacologic analysis of a set of chemokine receptors with multiple endogenous ligands using assays for G protein signaling, β-arrestin recruitment, and receptor internalization. We found that chemokines targeting the same receptor can display marked differences in their efficacies for G protein- or β-arrestin-mediated signaling or receptor internalization. This ligand bias correlates with changes in leukocyte migration, consistent with different mechanisms underlying the signaling downstream of these receptors induced by their ligands. These findings demonstrate that biased agonism is a common and likely evolutionarily conserved biological mechanism for generating qualitatively distinct patterns of signaling via the same receptor in response to different endogenous ligands.

Keywords:  Arrestin; Biased Agonism; Chemokines; G Protein-coupled Receptors (GPCR); G Proteins; Signaling

Mesh:

Substances:

Year:  2013        PMID: 24145037      PMCID: PMC3853256          DOI: 10.1074/jbc.M113.479113

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Knock out models to dissect chemokine receptor function in vivo.

Authors:  Christine A Power
Journal:  J Immunol Methods       Date:  2003-02       Impact factor: 2.303

2.  Enzyme fragment complementation: a flexible high throughput screening assay technology.

Authors:  Richard M Eglen
Journal:  Assay Drug Dev Technol       Date:  2002-11       Impact factor: 1.738

3.  A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions.

Authors:  T S Wehrman; W J Raab; C L Casipit; R Doyonnas; J H Pomerantz; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

Review 4.  Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery.

Authors:  Keith R Olson; Richard M Eglen
Journal:  Assay Drug Dev Technol       Date:  2007-02       Impact factor: 1.738

5.  TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.

Authors:  Guido Boerrigter; David G Soergel; Jonathan D Violin; Michael W Lark; John C Burnett
Journal:  Circ Heart Fail       Date:  2012-08-13       Impact factor: 8.790

Review 6.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

7.  Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states.

Authors:  M A Cox; C H Jenh; W Gonsiorek; J Fine; S K Narula; P J Zavodny; R W Hipkin
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

8.  Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands.

Authors:  D Gurwitz; R Haring; E Heldman; C M Fraser; D Manor; A Fisher
Journal:  Eur J Pharmacol       Date:  1994-03-15       Impact factor: 4.432

9.  Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7.

Authors:  Trudy A Kohout; Shelby L Nicholas; Stephen J Perry; Greg Reinhart; Sachiko Junger; R Scott Struthers
Journal:  J Biol Chem       Date:  2004-03-30       Impact factor: 5.157

10.  Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.

Authors:  Richard A Colvin; Gabriele S V Campanella; Jieti Sun; Andrew D Luster
Journal:  J Biol Chem       Date:  2004-05-17       Impact factor: 5.157

View more
  52 in total

1.  Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.

Authors:  Jun Jin; Philippe Colin; Isabelle Staropoli; Evelyne Lima-Fernandes; Cécile Ferret; Arzu Demir; Sophie Rogée; Oliver Hartley; Clotilde Randriamampita; Mark G H Scott; Stefano Marullo; Nathalie Sauvonnet; Fernando Arenzana-Seisdedos; Bernard Lagane; Anne Brelot
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

2.  Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.

Authors:  Jeffrey S Smith; Lowell T Nicholson; Jutamas Suwanpradid; Rachel A Glenn; Nicole M Knape; Priya Alagesan; Jaimee N Gundry; Thomas S Wehrman; Amber Reck Atwater; Michael D Gunn; Amanda S MacLeod; Sudarshan Rajagopal
Journal:  Sci Signal       Date:  2018-11-06       Impact factor: 8.192

3.  Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1.

Authors:  Julie Sanchez; Zil E Huma; J Robert Lane; Xuyu Liu; Jessica L Bridgford; Richard J Payne; Meritxell Canals; Martin J Stone
Journal:  J Biol Chem       Date:  2018-12-19       Impact factor: 5.157

4.  Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR.

Authors:  Laura M Wingler; Meredith A Skiba; Conor McMahon; Dean P Staus; Alissa L W Kleinhenz; Carl-Mikael Suomivuori; Naomi R Latorraca; Ron O Dror; Robert J Lefkowitz; Andrew C Kruse
Journal:  Science       Date:  2020-02-21       Impact factor: 47.728

5.  Biased signaling at chemokine receptors.

Authors:  Jenny Corbisier; Céline Galès; Alexandre Huszagh; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2015-01-22       Impact factor: 5.157

6.  Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.

Authors:  Jenny Corbisier; Alexandre Huszagh; Céline Galés; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

Review 7.  Pancreatic islet inflammation: an emerging role for chemokines.

Authors:  J Jason Collier; Tim E Sparer; Michael D Karlstad; Susan J Burke
Journal:  J Mol Endocrinol       Date:  2017-04-18       Impact factor: 5.098

8.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

9.  Small-molecule agonists of the RET receptor tyrosine kinase activate biased trophic signals that are influenced by the presence of GFRa1 co-receptors.

Authors:  Sean Jmaeff; Yulia Sidorova; Hinyu Nedev; Mart Saarma; H Uri Saragovi
Journal:  J Biol Chem       Date:  2020-04-03       Impact factor: 5.157

10.  Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.

Authors:  A Gilchrist; T D Gauntner; A Fazzini; K M Alley; D S Pyen; J Ahn; S J Ha; A Willett; S E Sansom; J L Yarfi; K A Bachovchin; M R Mazzoni; J R Merritt
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.